212 related articles for article (PubMed ID: 29098441)
21. Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis.
Woo HY; Youn JM; Bae SH; Jang JW; Cha JH; Kim HL; Chun HJ; Choi BG; Choi JY; Yoon SK
Korean J Hepatol; 2012 Mar; 18(1):32-40. PubMed ID: 22511901
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.
Vogt T; Hafner C; Bross K; Bataille F; Jauch KW; Berand A; Landthaler M; Andreesen R; Reichle A
Cancer; 2003 Nov; 98(10):2251-6. PubMed ID: 14601096
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
[TBL] [Abstract][Full Text] [Related]
24. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
Granito A; Marinelli S; Terzi E; Piscaglia F; Renzulli M; Venerandi L; Benevento F; Bolondi L
Dig Liver Dis; 2015 Jun; 47(6):518-22. PubMed ID: 25861840
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Lee KD; Hsiao CH; Lu YS; Huang CC; Shen YC; Hsu CH; Cheng AL
Oncology; 2012; 82(1):59-66. PubMed ID: 22310088
[TBL] [Abstract][Full Text] [Related]
26. Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE.
Huang W; You L; Yang S; Liu D; Liu M; Wang H; Wang P; Baikere P; Gu P; Abulikemu A; Yuan S; Fan X
J BUON; 2016; 21(4):909-916. PubMed ID: 27685913
[TBL] [Abstract][Full Text] [Related]
27. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
28. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
29. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
[TBL] [Abstract][Full Text] [Related]
30. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.
Sanoff HK; Kim R; Ivanova A; Alistar A; McRee AJ; O'Neil BH
Invest New Drugs; 2015 Apr; 33(2):505-9. PubMed ID: 25613083
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
Govindarajan R; Siegel E; Makhoul I; Williamson S
Am J Clin Oncol; 2013 Jun; 36(3):254-7. PubMed ID: 22643560
[TBL] [Abstract][Full Text] [Related]
32. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
Kim SJ; Seo HY; Choi JG; Sul HR; Sung HJ; Park KH; Choi IK; Oh SC; Yoon SY; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2006 Apr; 57(4):436-42. PubMed ID: 16049620
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Sun W; Sohal D; Haller DG; Mykulowycz K; Rosen M; Soulen MC; Caparro M; Teitelbaum UR; Giantonio B; O'Dwyer PJ; Shaked A; Reddy R; Olthoff K
Cancer; 2011 Jul; 117(14):3187-92. PubMed ID: 21264839
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.
Pelizzaro F; Sammarco A; Dadduzio V; Pastorelli D; Giovanis P; Soldà C; Rizzato MD; Lombardi G; Lonardi S; Peserico G; Imondi A; Sartori A; Maddalo G; Farinati F
Dig Liver Dis; 2019 Dec; 51(12):1713-1719. PubMed ID: 31320302
[TBL] [Abstract][Full Text] [Related]
35. Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK; Blanc JF; Miles S; Ganten T; Trojan J; Cebon J; Liem AK; Lipton L; Gupta C; Wu B; Bass M; Hollywood E; Ma J; Bradley M; Litten J; Saltz LB
Oncologist; 2017 Jul; 22(7):780-e65. PubMed ID: 28592620
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
37. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.
Shao YY; Wu CH; Lu LC; Chan SY; Ma YY; Yen FC; Hsu CH; Cheng AL
J Hepatol; 2014 Feb; 60(2):313-8. PubMed ID: 24036008
[TBL] [Abstract][Full Text] [Related]
38. Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma.
Shakado S; Iwata K; Tsuchiya N; Kunimoto H; Yotsumoto K; Fukunaga A; Kuno S; Tanaka T; Sakurai K; Iwashita H; Hirano G; Yokoyama K; Morihara D; Nishizawa S; Takeyama Y; Irie M; Sohda T; Kora S; Yoshimitsu K; Sakisaka S
Hepatogastroenterology; 2014 May; 61(131):557-62. PubMed ID: 26176035
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
[TBL] [Abstract][Full Text] [Related]
40. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]